The murine mutation (Cbl-c Δex7) occurred in a mammary tumor that arose in a genetically engineered mouse model–the C3(1) SV40 Large T antigen transgenic mouse model of breast cancer [28, 29]. This evidence concerns the gene CBLC and breast carcinoma.